Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial
Achieving a clinically significant benefit of ovarian cancer early detection will require prolonging the interception window through judicious combination of first- and second-line tests.
Authors
- Jane M Lange (ORCID: https://orcid.org/0000-0002-0014-9679)
- Marc D. Ryser (ORCID: https://orcid.org/0000-0002-4990-0849)
- Andy Ryan (ORCID: https://orcid.org/0000-0002-5359-9534)
- Jason Xu (ORCID: https://orcid.org/0000-0001-5472-3720)
- Raphaël Morsomme (ORCID: https://orcid.org/0000-0002-7421-6977)
- Aleksandra Gentry‐Maharaj (ORCID: https://orcid.org/0000-0001-7270-9762)
- Shannon T. Holloway (ORCID: https://orcid.org/0009-0005-6757-7503)
- Kemal Çag̃lar Gög̃ebakan (ORCID: https://orcid.org/0000-0001-5556-4194)
- Ruth Etzioni (ORCID: https://orcid.org/0000-0002-9164-6370)
- Usha Menon (ORCID: https://orcid.org/0000-0003-3708-1732)
- Sophia Apostolidou (ORCID: https://orcid.org/0000-0003-2659-0451)
Institutions
- Statistical and Applied Mathematical Sciences Institute (US)
- Oregon Health & Science University (US)
- Duke University (US)
- Fred Hutch Cancer Center (US)
- MRC Clinical Trials Unit at UCL (GB)
- London Women's Clinic (GB)
- Duke Medical Center (US)
- Oregon Health and Science University Hospital (US)
- University College London (GB)
Publication Details
- Journal
- Cancer Epidemiology Biomarkers & Prevention
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1158/1055-9965.epi-25-0498
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00